Syngene Q4 Review - Growth Trajectory Maintained; Outlook Upbeat: ICICI Direct
Syngene Internation R&D facility (image Company website).

Syngene Q4 Review - Growth Trajectory Maintained; Outlook Upbeat: ICICI Direct

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Syngene International Ltd.'s FY21 revenue grew 8.6% year-on-year to Rs 2,184 crore driven by steady growth across all divisions.

Adjusting for loss of export incentives, revenues grew 12% in FY21.

Ebitda margins remained flat YoY at 30.8% with better gross margins being offset by higher employee cost amid higher headcount.

Ebitda grew 8.7% YoY to Rs 672 crore. Adjusted profit after tax grew 4.4% YoY to Rs 382 crore.

Delta vis-a-vis Ebitda was due to higher depreciation and lower other income partially offset by lower tax rate.

Click on the attachment to read the full report:

ICICI Direct Syngene Q4FY21 Result Review.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.